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Background: P2X7, a purinergic receptor, plays important roles in inflammatory diseases, but recently its expression
has been found in several tumors, suggesting a potential role as a cancer cell biomarker. Moreover, the relative
amount of P2X7 varies among human individuals due to numerous single nucleotide polymorphisms resulting in
either a loss- or gain-of-function; the P2X7 gene is highly polymorphic, and polymorphisms in the promoter or
coding region may modify its expression or function. A polymorphism in exon 13 of the P2X7 receptor gene at
the +1513 position (Glu496Ala substitution, corresponding to SNP rs3751143) has been shown to eradicate the function
of this receptor and has been correlated with histological variants and clinical parameters in thyroid cancer. Until now, no
data regarding P2X7 expression and polymorphisms in lung cancer have been published; based on these premises, we
decided to evaluate the impact of the P2X7 expression and polymorphisms in ninety-seven cases of non-small cell lung
cancer (NSCLC).
Results: No significant difference in the genotype frequency of the A1513C polymorphism was found between the
two histological variants of NSCLC, adenocarcinoma and squamous cell carcinoma, and no statistically significant
associations were observed between P2X7 protein expression and the main clinico-pathological characteristics of the
NSCLC patients.
Conclusions: Based on our results, P2X7 expression and polymorphisms seem to have no potential impact in patients
with non-small cell lung cancer; however, further studies will surely provide deeper insights regarding the role of this
receptor at the clinical level in NSCLC.
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ATP-gated P2X7 receptors (P2X7) comprise a unique
family of extracellular ATP-activated plasma membrane
ion channels expressed in hematopoietic and epithelial
cells. P2X7 receptors have been extensively studied in
immune cells where their activation leads to the rapid
release of pro-inflammatory cytokines and the initiation
of the inflammatory cascade. As such, P2X7 represent a
pharmaceutical target for the treatment of inflammatory
diseases. Recently, P2X7 expression has been found in
several types of tumors [1-5], and P2X7 expression has
been suggested as a potential cancer cell biomarker. Upon
ATP stimulation, tumor cells can use P2X7 signaling in* Correspondence: laura.boldrini@med.unipi.it
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unless otherwise stated.different scenarios: i) as a reaction to this death-related
signal, tumor cells can downregulate P2X7 to avoid apop-
tosis, or ii) as a cancer-promoting signal, P2X7 signaling
can promote survival and enhanced invasion of new
niches. The high levels of extracellular ATP found in tu-
mors could represent a stressful stimulus for cancer cells
by initiating P2X7-driven cell death. Therefore, the in-
creased P2X7-dependent invasiveness of cancer cells
could be an escape strategy to flee the noxiously high
levels of ATP. The use of specific P2X7 antagonists could
be a new, alternative way to reduce the development of
cancer metastases and improve the efficacy of conven-
tional treatments [6].
The P2X7 gene is highly polymorphic, and polymor-
phisms in the promoter or coding region may modify its
expression or function. A polymorphism in exon 13 of the
P2X7 receptor gene at the +1513 position (Glu496Alal Ltd. This is an Open Access article distributed under the terms of the Creative
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shown to eradicate the function of this receptor and has
been correlated with histological variants and clinical pa-
rameters in thyroid cancer [7]. Until now, no data existed
regarding P2X7 expression and polymorphisms in lung
cancer; Fernando et al. reported that subjects that carry
one or two copies of SNP rs3751143 exhibit an enhanced
susceptibility to extrapulmonary tuberculosis, suggesting
the potential impact of this polymorphism at the clinical
level in lung tissue [8]. Based on these premises, we de-
cided to evaluate the impact of P2X7 expression and poly-




This study was conducted in 97 patients with NSCLC,
including 50 with adenocarcinoma (ADC), 45 with
squamous cell carcinoma (SCC), and 2 with large-cell
carcinoma (LCC). The median age at diagnosis was
68 years (range: 46–85, mean: 67.37). Patients’ TNM
classification was collected whenever available (80
cases) as follows: 12 T1, 45 T2, 17 T3, and 6 T4; and
26 cases with negative lymph node status, 49 with po-
sitive lymph node status (23 N1, 26 N2), and 5 with Nx
status (Table 1).Table 1 Correlations between P2X7 protein and the main
clinico-pathological characteristics of the NSCLC patients
Characteristic P2X7 protein expression (%) p
Low High
Age
≤68 years 26 (50) 26 (50) 0.74
>68 years 24(53.3) 21(46.7)
Gender
Males 38(50.7) 37(49.3) 0.74
Females 12(54.5) 10(45.5)
Histology
ADC 27 (54) 23 (46) 0.88
SCC 22 (48.9) 23(51.1)
LCC 1 (50) 1 (50)
Tumor stage
T1 (T1a-T1b) 4 (33.3) 8 (66.7) 0.08
T2 (T2a-T2b) 26(57.8) 19(42.2)
T3 11(64.7) 6 (35.3)
T4 1 (16.7) 5 (83.3)
Lymph-node status
Negative 11 (42.3) 15 (57.7) 0.08
Positive 31 (63.3) 18 (36.7)
Nx 0 (0) 5 (100)P2X7 immunohistochemistry
Immunohistochemical expression of P2X7 was evaluated
as the percentage of tumor cells displaying immunoreac-
tivity. At least 1,000 cancer cells (100 cells in 10 HPFs)
were counted for each section. The median value of
P2X7 (30% of tumor positive cells) was used as a cut-off
value to distinguish tumors with low P2X7 expression
levels from those with high expression levels. There were
50 cases with low expression (11 negative, 17 with 10-
15%, and 22 with 20-30% of tumor cells displaying im-
munoreactivity), while 47 samples showed high P2X7
immunohistochemical expression (30-90% immunore-
activity). The staining intensity was analyzed by distin-
guishing four categories: negative (0), weak staining (+),
intermediate staining (++) and strong staining (+++).
There was a good concordance between P2X7 percentage
and intensity (chi-squared test, p = 0.01). Normal bronchial
epithelial cells were used as internal positive controls for
P2X7 staining. Negative controls were conducted by omit-
ting the primary antibodies. Figure 1 shows representative
P2X7 immunohistochemistry analyses in lung cancer.
P2X7 polymorphism analysis
The A1513C SNP of P2X7 was genotyped by PCR/RFLP;
Figure 2 shows a representative example. Regarding this
polymorphism, the allelic frequencies of the A/A, A/C,
and C/C genotypes in the whole cohort of NSCLC pa-
tients were 55.7% (54 of 97), 40.2% (39 of 97), and 4.1%
(4 of 97), respectively. Therefore, the frequency of the
minor allele was 0.2, resulting in Hardy-Weinberg equi-
librium and a value within the range found in other pub-
lished European reports [9].
We then analyzed minor allele frequency within the
histotypes subgroups. No significant difference in the
genotype frequency of the A1513C polymorphism was
found between the two histological variants or among
the main clinico-pathological characteristics of NSCLC
patients (data not shown).
P2X7 expression and clinico-pathological characteristics
We determined whether P2X7 expression was correlated
with the main clinico-pathological characteristics. No
statistically significant associations were observed be-
tween P2X7 protein expression and any of the main
clinico-pathological characteristics of the NSCLC pa-
tients (Table 1).
Discussion
P2X7 was originally thought to be restricted to cells of
hematopoietic lineages. However, it is now evident that
P2X7 is also present in other cell lineages and in va-
rious neoplastic cells, particularly those arising from
hematopoietic and epithelial lineages [10,11]. P2X7 is
overexpressed in several human cancers [12], conferring
Figure 1 Immunohistochemical staining of P2X7 in lung cancers. (A and C) Low P2X7 expression levels in ADC (5%, 1+) and SCC
(15%, 1+), respectively. (B and D) High P2X7 expression levels in ADC (80%, 2+) and SCC (70%, 2+), respectively. Original magnification, 10X.
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vation induces a number of well-established downstream
signaling events, such as promoting cell proliferation or
inducing cell death, via a number of different intracellular
pathways. These observations raise the obvious issue of
whether this receptor might be a useful marker as well as
a novel target for therapy. Until now, few data existed re-
garding P2X7 expression in lung cancer. In this study, we
have evaluated P2X7 expression in ninety-seven NSCLC
samples by immunohistochemistry, evaluating the per-
centage of tumor cells displaying immunoreactivity. Ma-
lignant lung tissue showed P2X7 staining in most cases
(86/97, 88.6%), with a good concordance between percent-
age and intensity of immunoreactivity. Then, we used the
median value of tumoral positive cells as a cut-off to dis-
tinguish tumors with low P2X7 expression levels from
those with high expression levels. No statistically signifi-
cant associations were observed with the two histological
variants of NSCLC, adenocarcinoma and squamous cell
carcinoma, or with the main clinico-pathological charac-
teristics of the lung cancer patients.
Polymorphic variants of P2X7 are also attracting con-
siderable attention in human health and disease. P2X7
SNPs have been associated with various diseases. The ro-
bust association of SNP rs3751143 with increased suscep-
tibility to tuberculosis [13] is most likely due to impaired
P2X7-mediated killing of intracellular mycobacteria within
macrophages [14,15]. However, the association of P2X7
SNPs with other diseases has been examined in a variety
of other studies, with many failing to find significant asso-
ciations [16]. The majority of these studies has small sam-
ple sizes and thus lacks sufficient statistical power todetect whether a significant association exists. In line with
this finding, we also found in this study no significant
difference in the genotype frequency of the A1513C
polymorphism between the two histological variants or
among the main clinico-pathological characteristics of
NSCLC patients. Future studies examining the associ-
ation of P2X7 SNPs with lung cancer will benefit from
the development of high-throughput genotyping and
the collection of large disease cohorts. Moreover, given
the highly polymorphic nature of the P2X7 gene, future
genetic association studies will need to include ana-
lysis of P2X7 haplotypes and the detailed phenotypic
characterization of the encoded receptors.
It will also be of importance to determine the relative ef-
fectiveness of P2X7 therapeutics in relation to P2X7 iso-
forms and polymorphic variants in NSCLC. The role of
P2X7 purinergic receptors in anticancer immune response
and response to chemotherapy is not clear. Chemotherapy
fails in the absence of the purinergic receptor in breast
and colon cancer [17], but loss-of-function alleles in P2X7
do not affect overall survival in NSCLC patients, irrespect-
ive of the administration and type of chemotherapy [18].
A possible explanation for this difference is that bronchial
carcinomas may be subjected to a less vigorous immuno-
surveillance than tumors located in other organs, such as
the mammary gland or the colic mucosa.
Conclusions
Based on our results, P2X7 expression and polymor-
phisms seem to have no potential impact in patients
with non-small cell lung cancer; however, further stud-
ies, including micro-RNA-mediated gene regulation and
Figure 2 P2X7 polymorphism. Upper panel: The A1513C
polymorphism of P2X7 was detected by restriction fragment length
polymorphism (RFLP) analysis, as described in the Materials and
Methods section. The PCR product was digested with HhaI and run
on a 2% agarose gel. First lane, 100 bp marker; lane A, wild-type A/A
(223 bp); lane B, heterozygote A/C (134 bp); lane C homozygote C/C
(89 bp); last lane, negative control with no DNA added. Lower
panel: sequencing analysis of PCR-RFLP products A, B, and C of the
upper panel (wt, heterozygote and homozygote, respectively).
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insights into the results of our study.Materials and methods
Patients
Ninety-seven NSCLC patients were retrospectively se-
lected from patients operated at the Unit of Thoracic
Surgery of the A.O.U.P. between 2005 and 2012. Histo-
logical diagnoses were independently formulated by
two pathologists (G.F. and G.A.) according to the World
Health Organization classification [19,20]. Clinico-
pathological characteristics were collected in eighty
cases. This study was conducted in compliance with
the Helsinki Declaration and was approved by the Eth-
ics Committee of the Institutuion. All of the patients
gave their informed consent to analyses.P2X7 immunohistochemistry
Five-micrometer thick tumor sections were stained with
anti-human P2X7 (Abcam, Cambridge, UK, 1:100 dilu-
tion) antibody in an automated immunohistochemistry
processor (Immunostainer Benchmark XT; Ventana and
Tuckson). For the detection of P2X7, sections were cut
from formalin-fixed, paraffin-embedded blocks, deparaffi-
nized with xylene, and rehydrated by sequential passages
through decreasing (from 100% to 80%) concentrations of
ethanol. Endogenous peroxidase activity was blocked by a
30-minute incubation at room temperature with methanol
containing 3% H2O2. Tissue sections were then incubated
at 98°C for 40 minutes in Target retrieval solution pH 9.0
(Dako); after several rinses in wash buffer (Dako), tissue
sections were incubated overnight at 4°C with rabbit poly-
clonal anti-P2X7 antibody (ABCAM, 1:100). After incuba-
tion with the primary anti-antibody, tissue sections were
rinsed twice in PBS and incubated for 30 minutes at room
temperature with Dako Envision System HRP-conjugated
rabbit antibodies. Tissue sections were then washed in
PBS, and peroxidase activity was detected by incubation
for 6 to 10 minutes at room temperature with Dako
Liquid diaminobenzidine (DAB) Substrate Chromogen
System (Dako). Counterstaining was conducted with
Mayer's hematoxylin (Sigma-Aldrich).
DNA isolation
After manual tumor macrodissection, DNA was isolated
from 10-μm sections of formalin-fixed and paraffin-
embedded (FFPE) tissue specimens using the QIAamp
DNA Mini Kit (Qiagen), according to the manufac-
turer’s instructions.
P2X7 polymorphism analysis
The A1513C SNP of P2X7 was genotyped by PCR/RFLP
using the following primers: forward, 5′-TTCCTGGA
CAACCAGAGGAG-3′; reverse, 5′-AGGAACTGCAGG
ACGTGTCT-3′. Cycling conditions were as follows:
95°C for 4 min, 40 cycles of 95°C for 30 s, 58°C for 30 s
and 72°C for 45 s, with a final 10-min extension at 72°C.
PCR products were digested at 37°C for 16 h with 5.0 U
of HhaI (Fermentas, Thermo Fisher Scientific, Milan,
Italy). Digested products were run on a 2% agarose gel,
which was stained with ethidium bromide and visualized
using a UV transilluminator.
Statistical analysis
One-way analysis of variance and chi-squared tests were
used to determine the association between P2X7 ex-
pression and the polymorphism with the different pa-
rameters. Statistical analyses were performed using the
JMP10 software, and a two-tailed p value <0.05 was con-
sidered significant.
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